Companies · Biotechnology

Verinata Health Inc

Redwood City · Biotechnology

Diligence memoA one-page analyst read on Verinata Health Inc — recommendation, valuation, rhythm, risks.
$56.2M
Total raised · real
3
Rounds
0.0×
Latest step-up
Top 17%
Sector rank · raised
Series C
Latest stage · inferred · Mon Apr 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Verinata Health Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.02× the median modeled value of Series C Biotechnology companies in 2010–2012 (19 peers) — value vs value, same stage and era.
Dormant
  • Last raise 14.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Verinata Health Inc is one of 4293 Biotechnology companies tracked from Redwood City. By capital raised it ranks in the upper tier (ahead of 84% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries A · 2009-10-02 Raised $9.0M (real) Modeled valuation $325M (est)$9.0M$325MSeries A2009Series C · 2011-07-15 Raised $46M (real) Modeled valuation $1.9B (est)$46M$1.9BSeries C2011Series C · 2012-04-30 Raised $750K (real) Modeled valuation $31M (est)$750K$31MSeries C2012+$46M+$750KCumulative $56M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$9.0M · 2009
Series C$46.4M · 2011no Series B on file
Series C extension$750K · 2012

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$30.7M
Base estimate est.
$2.3M
Conservative case
$80.9M
Upside case
$5.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $325.4M · 2009-10-022009Series C · modeled $1.9B · 2011-07-15Series C · modeled $30.7M · 2012-04-302012
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
6.0 yr
Elapsed time used
14.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
15 mo
Avg between rounds
$21.8M/yr
Capital velocity
16.7 yr
On record since
2009
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.8× above median
This company$56.2M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.0× of median
This company$750K
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$30.7M
Sector median$64.2M

Raised more than 84% of sector peers (real $). Modeled value above 36% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #17 of 19.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Insmed Inc · Series C Raised $83.7M · modeled $3.4B (est)Infinity Pharmaceuticals, Inc. · Series C Raised $78.5M · modeled $3.2B (est)Ultragenyx Pharmaceutical Inc. · Series C Raised $108.8M · modeled $3.1B (est)Relypsa Inc · Series C Raised $292.3M · modeled $2.7B (est)Knopp Neurosciences Inc. · Series C Raised $72.9M · modeled $2.5B (est)Nevro Corp · Series C Raised $78.6M · modeled $2.4B (est)Foundation Medicine, Inc. · Series C Raised $115.5M · modeled $2.3B (est)Puma Biotechnology, Inc. · Series C Raised $55.0M · modeled $2.3B (est)Aria Diagnostics, Inc. · Series C Raised $65.2M · modeled $2.2B (est)IntegenX Inc · Series C Raised $133.9M · modeled $2.0B (est)SARcode Corp · Series C Raised $99.6M · modeled $1.8B (est)Selexys Pharmaceuticals Corp · Series C Raised $89.1M · modeled $1.8B (est)Verinata Health Inc (this company) Raised $56.2M · modeled $30.7M (est)Verinata Health Inc
CompanyStageRaised · realValue · estvs peer med.
Insmed IncSeries C$83.7M$3.4B1.71×
Infinity Pharmaceuticals, Inc.Series C$78.5M$3.2B1.61×
Ultragenyx Pharmaceutical Inc.Series C$108.8M$3.1B1.54×
Relypsa IncSeries C$292.3M$2.7B1.33×
Knopp Neurosciences Inc.Series C$72.9M$2.5B1.23×
Nevro CorpSeries C$78.6M$2.4B1.20×
Foundation Medicine, Inc.Series C$115.5M$2.3B1.15×
Puma Biotechnology, Inc.Series C$55.0M$2.3B1.13×
Aria Diagnostics, Inc.Series C$65.2M$2.2B1.08×
IntegenX IncSeries C$133.9M$2.0B1.00×
SARcode CorpSeries C$99.6M$1.8B0.89×
Selexys Pharmaceuticals CorpSeries C$89.1M$1.8B0.88×
Verinata Health Inc this companySeries C$56.2M$30.7M0.02×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$9.0M2009-10-02$40.9M$325.4M90%
Series C$46.4M2011-07-15$309.7M$1.9B90%
Series C$750K2012-04-30$5.0M$30.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$9.0M2009-10-02
    • First recorded raise — entered as Series A.
  2. Series C$46.4M2011-07-15
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 5.2× larger than the prior — scaling up.
  3. Series C$750K2012-04-30
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 61.9× smaller than the prior — bridge or down round.
Intelligence
2013 ~Q3
Modeled next raise · ~15mo cadence
$750K
Modeled next size est.range $750K$1.2M
0.0×
Last step-up
$21.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
JEFF BIRD6 other2009-10
Bill Ericson4 other2009-10
Michael Hunkapiller3 other2009-10
Phyllis Whiteley2 other2009-10
Alfred L. Merriweather2012-04
Caren L. Mason2012-04
Caren Mason2011-07
Richard Rava2009-10
Registry & provenance

Verinata Health Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1439603
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Raindance Technologies IncBiotechnologySeries C$105.7M$1.7Bnetwork1 shared operator · same sector · same stage
Fluidigm CorpBiotechnologySeries C$111.0M$3.1Bnetwork1 shared operator · same sector · same stage
AmbAgon Therapeutics Inc.BiotechnologySeries C$55.4M$35.9Msame sector · same stage
Neogenix Oncology IncBiotechnologySeries C$80.8M$30.6Msame sector · same stage
ReWalk Robotics Ltd.BiotechnologySeries C$94.0M$36.6Msame sector · same stage
Drais Pharmaceuticals IncBiotechnologySeries B$20.0M$793.8Mnetwork1 shared operator · same sector
Fibrocell Science, Inc.BiotechnologySeries C$108.6M$36.9Msame sector · same stage
Akari Therapeutics PlcBiotechnologySeries C$140.5M$34.1Msame sector · same stage
Frequently asked
How much funding has Verinata Health Inc raised?
Verinata Health Inc has raised approximately $56.2M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Verinata Health Inc's estimated valuation?
Provath's modeled valuation for Verinata Health Inc is approximately $30.7M (modeled range $2.3M–$80.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Verinata Health Inc at?
Verinata Health Inc's latest modeled financing stage is Series C. Its most recent recorded round closed around Mon Apr 30.
What does Verinata Health Inc do and where is it based?
Verinata Health Inc operates in the Biotechnology sector, based in Redwood City.
Explore related

See where Verinata Health Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Verinata Health Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.